UCLA

UCLA Previously Published Works

Title

Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Permalink

<https://escholarship.org/uc/item/1dh5297w>

Journal

CNS drugs, 29(5)

ISSN

1172-7047

Authors

Mamoun, Michael
Bergen, Andrew W
Shieh, Jennifer
et al.

Publication Date

2015-05-01

DOI

10.1007/s40263-015-0243-1

Peer reviewed

Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date

Michael Mamoun¹ · Andrew W. Bergen² · Jennifer Shieh³ · Anna Wiggins⁴ · Arthur L. Brody^{1,5}

© Springer International Publishing Switzerland (outside the USA) 2015

Abstract For the past 30 years, research examining predictors of successful smoking cessation treatment response has focused primarily on clinical variables, such as levels of tobacco dependence, craving, and self-efficacy. However, recent research has begun to determine biomarkers (such as genotype, nicotine and metabolite levels, and brain imaging findings) that may have utility in predicting smoking cessation. For genotype, genes associated with nicotinic acetylcholine receptors (nAChRs) and related proteins have been found to predict response to first-line medications (e.g. nicotine replacement therapy [NRT], bupropion, or varenicline) or quitting over time without a controlled treatment trial. For nicotine and metabolite levels, function of the cytochrome P450 2A6 liver enzyme, which can be assessed with the nicotine metabolite ratio or via genotype, has been found to predict response, with slow nicotine metabolizers having less severe nicotine dependence and a greater likelihood of quitting with NRT than

normal metabolizers. For brain imaging, decreased activation of brain regions associated with emotion regulation and increased connectivity in emotion regulation networks, increased responsiveness to pleasant cues, and altered activation with the Stroop effect have been found in smokers who quit with the first-line medications listed above or counseling. In addition, our group recently demonstrated that lower pre-treatment brain nAChR density is associated with a greater chance of quitting smoking with NRT or placebo. Several of these studies found that specific biomarkers may provide additional information for predicting response beyond subjective symptom or rating scale measures, thereby giving an initial indication that biomarkers may, in the future, be useful for guiding smoking cessation treatment intensity, duration, and type.

✉ Arthur L. Brody
abrody@ucla.edu

¹ Departments of Research and Psychiatry, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA

² Center for Health Sciences, SRI International, Menlo Park, CA, USA

³ Department of Neurology, University of California at Los Angeles, Los Angeles, CA, USA

⁴ Department of Psychiatry, University of Southern California, Los Angeles, CA, USA

⁵ Department of Psychiatry, University of California at Los Angeles, 300 UCLA Medical Plaza, Suite 2200, Los Angeles, CA 90095, USA

Key Points

Prior research examining predictors of smoking cessation has focused on clinical variables, such as levels of tobacco dependence, craving, and self-efficacy.

Biomarkers that may have utility in predicting smoking cessation in response to specific treatments include genotypes (e.g. nicotinic acetylcholine receptor [nAChR] genes), nicotine metabolite ratios, and brain imaging findings (e.g. regional brain activation in response to cigarette cues and nAChR density).

In several studies, biomarkers have been found to provide additional predictive power beyond subjective symptoms and rating scale scores.

1 Introduction

For the past 30 years, research examining predictors of successful smoking cessation has focused primarily on clinical variables, with the most commonly studied being related to smoking, demographics, psychological symptoms, and treatment. Smoking-related factors associated with positive cessation outcomes include lower baseline craving [1, 2], severity of nicotine dependence [3–8], and number of cigarettes smoked per day [9–14]. Demographic variables shown to be helpful include higher educational level [15–18], older age [19, 20], and being married [21]. Studies have shown mixed results regarding gender as a determinant of successful cessation [9, 12, 20–24]. Numerous psychological factors have been associated with a positive response to treatment, including high baseline levels of self-efficacy [17, 18, 25–27], readiness and motivation to quit [16, 24, 28], low stress levels [29], low negative affect [30], no history of depression [31], and low anger [32]. Treatment-related factors include use of behavioral support [13, 33], adherence [34, 35], and absence of lapses during early treatment [36]. While these clinical factors have been extensively studied and utilized in the treatment of cigarette smokers for years, recent studies in the fields of genetics, nicotine metabolism, and brain imaging have begun to elucidate biomarkers associated with prediction of treatment response. To enable a narrative review of genetic, metabolic, and brain imaging biomarkers of response to smoking cessation therapies, we searched the genetics, pharmacology, pharmacogenetics, and imaging literature in the PubMed database for articles published in English from the last 20 years. Search terms included ‘clinical trial’, ‘gene’, ‘genetic analysis’, ‘smoking cessation’, ‘randomized’, ‘metabolism’, ‘plasma nicotine’, ‘cotinine’, ‘magnetic resonance imaging’, ‘spectroscopy’, ‘single photon emission computed tomography’, and ‘positron emission tomography’ for the years 1998–2015, and selected author surnames. In total, ~650 abstracts were reviewed for this paper.

2 Genetic Biomarkers

Smoking is a complex behavior with both genetic and environmental determinants. Twin studies suggest that additive genetic factors account for approximately 45–85 % of variability of smoking initiation and persistence [37–40], as well as up to 75 % of the variability in nicotine dependence [41–46]. Other studies suggest that 40–60 % of individual differences in the ability to successfully quit may be attributable to additive genetic effects [47–49]. Meta-analyses of genome-wide association

scans (GWASs) of cigarette smoking behaviors [50–55] provide genome-wide (GW) significant evidence at single nucleotide polymorphisms (SNPs) in the chr8p11.21 and chr15q25.1 nicotinic acetylcholine receptor (nAChR) gene regions, chr19q13.2 *EGLN2* and *CYP2A6* genes, and the 9q34.2 dopamine β -hydroxylase *DBH* locus. Additive score analysis of GW significant SNPs associated with cigarette consumption accounts for ~1 % of the variance [56]. The aggregate effect of >500,000 common SNPs explains 10–30 % of the variance of multiple nicotine and alcohol substance use/dependence traits [57]. The lower effect sizes accounted for by all GW significant SNPs, and that due to all common SNPs, compared with the estimated genetic effects from pedigree-based genetic epidemiology modeling, i.e. the ‘missing heritability’ problem [58], outlines the possible effects and limitations of pharmacogenetic biomarkers.

Most pharmacogenetic studies of prospective abstinence in randomized controlled trials (RCTs) of smoking cessation therapies (‘studies’) have focused on candidate genes (CGs) in substance dependence-relevant neurotransmitter pathways, or CGs that influence the metabolism of, or response to, nicotine, bupropion, or varenicline [59–63]. Most studies of abstinence are of a small number of selected SNPs or variable number of tandem repeat polymorphisms (VNTRs) in a single RCT. There are a smaller number of studies of two or more RCTs using association or linkage disequilibrium (LD) criteria to nominate SNPs or VNTRs into panels to interrogate CGs [61–69]. Other approaches include GW pooled allelotyping [70–72], risk score analysis based on CG or GW a priori hypotheses [73–76], or pharmacokinetic hypotheses [77–81]. Studies using CG panels and stratifying by treatment, gender, nicotine metabolism, or dependence, have identified SNPs at *CHRNA2* [61], multiple nAChRs and *CYP2B6* [62], *SLC22A2* [63], *EPB41* and *CNR1* [64], *DRD1* [65], and at *DBH* [66].

SNP or haplotype (two or more SNPs) hypothesis-driven [82–87] studies of the chr15q25.1 nAChR locus [88–93] have included analyses of one to eight RCTs. In 400 participants from two RCTs randomizing participants to bupropion or placebo treatment [94, 95], Baker et al. [88] identified a significant association by haplotype, comprised of alleles from five SNPs (rs680244, rs569207, rs16969968, rs578776, rs1051730), previously associated with increased smoking heaviness [85], with reduced abstinence from baseline to end of treatment (EOT), with no difference in association by treatment. In 270 participants from one of two RCTs treating participants with combined bupropion, nicotine replacement therapy (NRT), and cognitive behavioral therapy (CBT) to 8 weeks post-quit, then randomizing individuals to CBT and telephone counseling versus general supportive

therapy via telephone for an additional 12 weeks, Sarginson et al. [89] identified association of rs680244, previously associated with decreased nicotine dependence [86], with increased abstinence at 1 year; there were no differences in association by therapy randomization. In a meta-analysis of 1581 participants from two RCTs [96, 97] randomizing individuals to nicotine or placebo transdermal patch [96] or to two levels of behavioral support while providing all participants with nicotine patch [97], and in the RCT providing two levels of behavioral support [97], Munafò et al. [90] identified association of the principal chr15q25.1 risk SNP rs1051730 [84] with reduced abstinence at 4 weeks. In one RCT randomizing smokers to five active therapies (nicotine lozenge, nicotine patch, bupropion, nicotine patch and nicotine lozenge, bupropion and nicotine lozenge) and placebo therapy [98], Chen et al. [91] identified association of a previously defined chr15q25.1 risk haplotype (three alleles defined by rs680244 and rs16969968) [85] with reduced abstinence at EOT in smokers randomized to placebo, and a haplotype-by-treatment interaction, reflecting the lack of association of haplotype with active treatment. In a meta-analysis including 2633 individuals from eight RCTs randomizing participants to NRT, bupropion, placebo, varenicline, and combined NRT and bupropion to EOT [94, 95, 98–101], and based on the hypothesis-generating meta-analysis of Saccone et al. [82], Bergen et al. [92] identified association with 6-month abstinence in smokers carrying either of the two smoking heaviness risk SNPs rs588765 and rs1051730; smokers randomized to NRT exhibited increased cessation, and smokers randomized to placebo exhibited reduced cessation; a significant genotype-by-treatment interaction effect was observed. In an analysis of 185 participants in an RCT randomizing participants to selegiline or placebo patch [102], Sarginson et al. [93] identified association of rs3813567, previously associated with nicotine dependence [84], with reduced abstinence in smokers randomized to selegiline at week 25, but not in smokers randomized to placebo; rs3813567 carriers randomized to selegiline exhibited higher levels of craving through treatment.

Studies that have identified associations of polymorphisms at chr19q13.2 metabolic genes *CYP2A6* (coding for cytochrome P450 [CYP] 2A6, the principal enzyme metabolizing nicotine [103]) and *CYP2B6* (coding for CYP2B6, the principal enzyme metabolizing bupropion [104]) with abstinence have included analyses motivated by prior hypotheses based on drug metabolism studies [105–107], a CYP2A6 enzyme activity model utilizing seven *CYP2A6* variants [108], or the use of LD [62] (see Sects. 3.3, 3.4).

3 Metabolic Biomarkers

3.1 Nicotine and Cotinine Levels

Nicotine and cotinine levels serve as markers of cigarette use and abstinence. Nicotine levels in plasma and urine correlate well with nicotine intake and can be measured through gas chromatography, high-performance liquid chromatography, and immunoassays [109]. Nicotine, like many other drugs, is metabolized by the liver enzyme CYP system. In humans, ~70–80 % of nicotine is converted to cotinine, largely mediated by the liver enzyme CYP2A6 [110]. Cotinine is further metabolized to its primary metabolite, *trans*-3'-hydroxycotinine (3HC), also by CYP2A6 [111]. Because of its long half-life (~16 h), cotinine (in plasma, urine, and saliva) is often used as a biomarker to reflect the recent use of cigarettes [112] and can also serve as verification of self-reported abstinence rates, typically for a 7-day period [109, 113].

3.2 Nicotine Metabolite Ratio

The ratio of 3HC to cotinine, termed the nicotine metabolite ratio (NMR) is used as a marker for overall nicotine clearance, and reflects individual variability in nicotine and cotinine metabolism due to variation in CYP2A6 activity, which is influenced by genetic variation and the environment [114–119]. Higher NMR indicates faster nicotine clearance and is associated with heavier smoking and lower cessation rates, possibly due to greater craving and nicotine withdrawal severity [78, 120–122]. NMR is stable in blood, plasma, and saliva at various conditions so that a single measurement of plasma NMR is reliable [123]. Other ratios of nicotine metabolites have and are being used as biomarkers of nicotine metabolism in pharmacogenetic or observational studies, e.g. the ratio of cotinine over nicotine or cotinine over the sum of nicotine and cotinine [79, 108, 124–126]. In an investigation by Patterson et al. [127], it was found that fast metabolizers of nicotine had lower quit rates with placebo, but rates were increased with bupropion treatment (10–34 %). Slow metabolizers had equal quit rates with placebo or bupropion (32 %), indicating that no further benefit was achieved with bupropion in slow metabolizers.

3.3 Cytochrome P450 (CYP) 2A6

Genetic variation that results in slower CYP2A6 activity significantly affects cigarette use, nicotine clearance, and nicotine metabolite levels [107, 115], with slow metabolizers having lower nicotine clearance and smaller NMRs, generally defined as the presence of one or two

reduced activity or null *CYP2A6* alleles [108, 124], or an NMR value in the lowest quartile or lower half of the distribution [79, 107, 128, 129]. Utilizing estimates of nicotine metabolism defined by *CYP2A6* genetic variation, Ho et al. [77] demonstrated that smokers of African ancestry with *CYP2A6* variants associated with low enzyme activity and randomized to nicotine gum or placebo therapy, were more likely to remain abstinent than smokers with *CYP2A6* variants associated with normal enzyme activity. Lerman et al. [78], who examined Caucasian smokers randomized to 6-month ('extended') versus 8-week ('standard') transdermal nicotine therapy found that smokers with *CYP2A6* variants associated with reduced nicotine metabolism benefit from extended transdermal therapy more than normal metabolizers and were more likely to remain abstinent at 24 weeks. In one RCT [98], Chen et al. [79] confirmed three hypotheses linking genetically-defined slow nicotine metabolism with decreased relapse risk: (a) slow-metabolizer status alone; (b) either slow-metabolizer status or randomization to active treatment; and (c) slow-metabolizer status and randomization to NRT.

In an RCT using transdermal nicotine or nicotine nasal spray, Lerman et al. [129] showed that NMR predicted smoking abstinence (EOT and 6-month follow-up) with transdermal nicotine treatment but not nasal spray. Schnoll et al. [130] validated the NMR as a predictor of abstinence in a single-arm trial of nicotine patch treatment at 8 weeks. In a prospective NMR-stratified RCT randomizing smokers to three treatments (two active and one placebo), Lerman et al. [128] identified an NMR-by-treatment interaction at EOT and at 6 months, whereas normal metabolizers randomized to varenicline exhibited significantly increased abstinence compared with normal metabolizers randomized to nicotine patch. The efficacies of varenicline and nicotine patch were equivalent among slow metabolizers. In an RCT randomizing African ancestry light smokers to nicotine gum or placebo, Ho et al. [77] showed that smokers in the lowest NMR quartile exhibited increased abstinence overall at 26 weeks, and at both EOT and 26 weeks in females.

In addition to being a biomarker for smoking cessation efficacy on NRT, *CYP2A6* slow metabolizers have been found to have other interesting associations, including smoking fewer cigarettes per day, later age of smoking onset, and smoking for a shorter duration prior to quitting [131]. In contrast to slow metabolism, rapid metabolism of nicotine may make the withdrawal process more abrupt, leading to more difficulty quitting and more severe dependence. In fact, smokers with rapid metabolizer alleles (*CYP2A6**1/*1B) report more serious withdrawal symptoms during cessation [132]

and have heavier smoking and lower cessation rates [120]. Furthermore, a neuroimaging study found that *CYP2A6* rapid metabolizers had significantly greater responses to visual cigarette cues than slow metabolizers in the amygdala, hippocampus, striatum, insula, and cingulate cortex [133]. It is notable that smokers in these studies were not receiving smoking cessation pharmacotherapy.

Given the large number of *CYP2A6* alleles that exist [106], as well as the influence of environmental factors on nicotine metabolism, the NMR may be a better biomarker than *CYP2A6* alone because it includes both genetic and environmental sources of variation in nicotine metabolism and clearance [120]. Variation in treatment response among smokers with multiple genes may guide personalized smoking cessation interventions in the future.

3.4 CYP2B6

Although the main enzyme responsible for nicotine metabolism is *CYP2A6*, genetic variation at *CYP2B6* leading to *CYP2B6* enzyme activity differences may also be important in smoking cessation treatment response. *CYP2B6* is the primary enzyme responsible for metabolism of the smoking cessation drug bupropion into its metabolite, hydroxybupropion [104]. In an RCT using bupropion and placebo [80, 81], smokers with a *CYP2B6* functional polymorphism (exon 9 1459C>T) resulting in decreased *CYP2B6* activity had increased relapse rates overall, and smokers randomized to bupropion with functional *CYP2B6* polymorphisms resulting in increased *CYP2B6* activity had increased abstinence rates. LD-motivated analyses of three RCTs randomizing smokers to varenicline, bupropion, and placebo [62] identified multiple *CYP2B6* SNPs associated with abstinence at EOT and at 1 year in smokers randomized to bupropion and overall. These analyses focused on 785 SNPs from 24 genes, representing 254 LD bins (genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism). One recent study identified a non-coding region in *CYP2B6* (rs8109525) which may affect nicotine metabolism indirectly via altering gene splicing and allelic expression [134]. Knowledge of an individual's *CYP2B6* status may be helpful in deciding whether or not to use bupropion for smoking cessation. In a double-blind, placebo-controlled, randomized trial, it was found that higher hydroxybupropion levels (rather than bupropion levels) corresponded to better smoking cessation outcomes [135]. These findings suggested that increasing the bupropion dose for *CYP2B6* slow metabolizers could improve smoking cessation outcomes.

4 Brain Imaging Biomarkers

An emerging area of research is the use of brain imaging to determine biomarkers for smoking cessation treatment response. Imaging modalities used for this research include anatomical magnetic resonance imaging (MRI), functional MRI (fMRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) (see Table 1 for a summary of results). Not only do these studies relate brain structure/function to treatment response but two studies appear to demonstrate that brain biomarkers are better predictors of outcome than clinical predictors.

In one of the earliest studies in this area [136], anatomical MRIs were obtained in adult smokers prior to treatment with nicotine patch (plus reduced nicotine cigarettes [RNCs]). Smokers with higher gray matter (GM) volumes in the left putamen and right occipital lobe, and lower GM volume in bilateral hippocampi and right

cuneus, were more likely to quit smoking. These results suggest that smoking abstinence is associated with higher pre-quit brain volume in regions that subserve habit learning and visual processing, and lower brain volume in regions that subserve long-term memory processes and visual information processing.

Several fMRI studies have demonstrated links between regional neural activation/deactivation in response to cigarette-related cues and quitting smoking with treatment. In an early study of this type [137], smokers underwent fMRI, during which they were presented with cigarette-related and control pictures followed by treatment with nicotine patch plus RNCs. Here, the amplitude of responses to smoking cues was larger in the thalamus than responses to control cues at baseline among future abstainers. In a second study of this type, smokers underwent fMRI, during which smoking-related pictures were presented, followed by treatment with NRT plus psychotherapy [138]. Smokers

Table 1 Brain imaging biomarkers of smoking cessation treatment response

References	Brain imaging modality	Treatment	Results predicting quitting
Froeliger et al. [136]	Anatomical MRI	Nicotine patch taper + RNCs	Increased gray matter in left putamen, right occipital lobe Decreased gray matter in bilateral hippocampus and right cuneus
McClernon et al. [137]	fMRI—cigarette vs. neutral cues	Nicotine patch taper + RNCs	Increased thalamus activation
Janes et al. [138]	fMRI—cigarette vs. neutral cues	Nicotine patch + gum/lozenge + individual counseling	Less bilateral insula, ACC, PCC, amygdala, PMC, inferior parietal cortex, parahippocampal gyrus, thalamus, putamen, cerebellum, PFC, and striate and extrastriate cortex Increased connectivity between emotion regulation networks
Hartwell et al. [139]	fMRI—cigarette vs. neutral cues	Varenicline	No group differences except when resisting cues
Versace et al. [140]	fMRI—cigarette, pleasant, and neutral cues	Varenicline, bupropion, or placebo	Higher reactivity to pleasant cues in post-visual association areas, dorsal striatum, medial PFC, and DLPFC
Krishnan-Sarin et al. [141]	fMRI—Stroop administration	CBT, CM, or both	Greater activation due to Stroop effect in the IFG, insula, thalamus, and ACC
Wheelock et al. [142]	fMRI—Stroop administration	Varenicline	Less activation due to Stroop effect in putamen and insula
Loughead et al. [143]	fMRI—n-back task	Brief counseling	Less left DLPFC activation and less suppression of PCC activity
Wheelock et al. [142]	MRS	Varenicline	No differences
Mashhoon et al. [144]	MRS	NRT	Greater dACC glutamate levels
Brody et al. [145]	2-FA PET	CBT, bupropion, or placebo	Trend for lower nAChR density in PFC, brainstem, and cerebellum
Brody et al. [146]	2-FA PET	Nicotine patch vs. placebo patch	Lower pretreatment nAChR density across all brain regions studied

2-FA 2-[F-18]fluoro-A-85380, ACC anterior cingulate cortex, CBT cognitive behavioral therapy, CM contingency management, dACC dorsal anterior cingulate cortex, DLPFC dorsolateral prefrontal cortex, fMRI functional MRI, IFG inferior frontal gyrus, MRI magnetic resonance imaging, MRS magnetic resonance spectroscopy, nAChR nicotinic acetylcholine receptor, NRT nicotine replacement therapy, PCC posterior cingulate cortex, PET positron emission tomography, PFC prefrontal cortex, PMC premotor cortex, RNCs reduced nicotine cigarettes

who did not quit had greater pre-treatment smoking-related cue activation across regions involved in sensory integration, arousal, and emotion. The authors concluded that pre-quit brain reactivity to smoking-related images is greater in smokers who do not quit, and that non-quitters have reduced pre-quit top-down control over interoceptive awareness and may be less able to regulate emotional responding to smoking-related images. Results from a third fMRI study of this type using cigarette-related and neutral cues did not find differences in regional brain activation between quitters and non-quitters who underwent treatment with varenicline [139]. However, during baseline fMRI scanning when smokers tried to resist craving, quitters demonstrated activation (compared with non-quitters) in a distributed brain network involved in alertness, learning, and memory.

In a related study using both cigarette-related cues and pleasant cues presented to smokers [140], fMRI scanning revealed that smokers who showed lower pretreatment levels of brain reactivity to pleasant cues than cigarette-related cues were less likely to be abstinent following treatment with medication plus counseling. Smokers with less response to pleasant cues also had higher levels of negative affect during the course of the quit attempt.

In addition to fMRI studies using craving and mood cues, three recent studies examined cognitive tasks, brain activity, and treatment response. For the first study [141], adolescent smokers underwent fMRI with Stroop administration, followed by treatment with CBT, contingency management, or both. Smokers with greater regional brain activation due to the Stroop effect had greater reductions in smoking. Study authors posited that adolescents with greater Stroop-related activation of cognitive control circuitry prior to behavioral therapy may be better able to decrease or quit smoking, possibly by more successfully exerting cognitive control in situations that might interfere with their quit effort. For the second study [142], smokers underwent fMRI with Stroop administration, followed by a course of treatment with varenicline. On pre-treatment fMRI scans, smokers who did not complete treatment (presumed relapsers) had increased fMRI activation with the Stroop effect in the putamen and insula compared with study completers (who either quit or had large decreases in the amount smoked). In both of the preceding studies, increased activity in the insula during a cognitive control task predicted an improved likelihood of quitting. For the third study [143], smokers underwent fMRI (in abstinence and satiety) during which they performed the n-back working memory task. These sessions were followed by brief counseling and an abstinence attempt for 1 week. Study results linked abstinence-induced decreases in left dorsolateral prefrontal cortical activation and reduced suppression of posterior cingulate cortex activity to treatment

outcome, thereby implicating the executive control and default mode networks, respectively, to the ability to maintain abstinence. Taken together, this series of fMRI studies has identified many regions as potentially being associated with several types of treatment response (Table 1), as well as some contradictory results and at least one negative finding. Future research could build on these initial studies by focusing on specific regional (e.g. insula or prefrontal cortical) and treatment-type hypotheses.

As for MRS studies, one study [144] examined dorsal anterior cingulate cortex (dACC) MRS glutamate (Glu/Cr) levels in smokers prior to treatment with NRT, and found that smokers who did not maintain abstinence had reduced dACC glutamate levels compared with smokers who did maintain abstinence. The authors concluded that MRS Glu/Cr ratio may be a neurobiological marker of glutamatergic dysfunction in relapse-vulnerable smokers. In contrast, a subsequent MRS study [142] did not find significant differences in baseline glutamate plus glutamine in study non-completers (presumed relapsers) compared with study completers (who substantially cut down or quit smoking) with varenicline.

Our group performed two recent PET scanning studies using the radiotracer 2-FA to examine the relationship between a marker for pretreatment $\alpha 4\beta 2^*$ nAChR density and response to smoking cessation treatment. The first of these studies [145] focused on changes in nAChR density from pre- to post-treatment with either CBT, bupropion, or placebo. In an exploratory analysis, pre-treatment markers for nAChR density had trend-level indications that lower nAChR density in three brain regions studied was associated with a greater likelihood of quitting. In the second study [146], using the same PET method, a relatively large sample of smokers underwent double-blind, placebo-controlled treatment with nicotine patch. Smokers with lower pretreatment nAChR density (a possible marker of less severe nAChR upregulation) across all brain regions studied were more likely to quit smoking, regardless of treatment group. Furthermore, pretreatment average nAChR densities provided additional predictive power for the likelihood of quitting beyond self-report measures. While it is recognized that the costly, time-consuming PET procedure used by our group is not likely to be used clinically, simpler methods for examining $\alpha 4\beta 2^*$ nAChR upregulation could be tested and applied in the future to help determine which smokers may need more intensive and/or lengthier treatment.

Most of the brain imaging studies reviewed in this section were described as preliminary or pilot work; however, some intriguing findings were reported that are worthy of future research. Novel findings include decreased activation of brain regions associated with emotion regulation and increased connectivity in emotion regulation networks,

increased responsiveness to pleasant cues, and altered activation with the Stroop effect in smokers who quit. Furthermore, our finding of lower pre-treatment nAChR density in smokers who quit was indicated preliminarily in one study and found to be significant in a second, indicating that smokers with greater objective evidence of brain nicotine exposure have more difficulty quitting than smokers with evidence for less nicotine exposure.

5 Conclusions

While clinical predictors of smoking cessation treatment response have been extensively studied, emerging evidence suggests that genetic, metabolic, and brain imaging biomarkers are useful in predicting response. Specifically, genes for nAChRs (and related proteins), determinants of nicotine metabolism, and brain imaging findings related to cigarette cue responses and nAChR levels have been found to predict response. Furthermore, several of these studies found that specific biomarkers may provide additional information for predicting response beyond subjective symptom or rating scale measures [136, 138, 143, 146]. Current research is focusing on clinical applicability of NMR [147], which is likely the most robust biomarker of treatment response found to date. Future research could focus on biomarkers with at least preliminary indications of association with treatment response in the fields of genetics (e.g. chr8p11.21 and chr15q25.1 regions of the nAChR) and brain imaging (e.g. insula and prefrontal cortical activation). Thus, these recent findings could, in the future, influence treatment intensity and duration, and perhaps also guide choice of treatment.

Acknowledgments This work was supported by grants from the National Institute on Drug Abuse (R01 DA20872), the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412), and the Tobacco-Related Disease Research Program (#23XT-0002) to Arthur L. Brody, and a grant from the National Institute on Drug Abuse (R21 DA33813) to Andrew W. Bergen. Michael Mamoun, Andrew W. Bergen, Arthur L. Brody, Jennifer Shieh and Anna Wiggins report no conflicts of interest.

References

- Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Cue-provoked craving and nicotine replacement therapy in smoking cessation. *J Consult Clin Psychol*. 2004;72(6):1136–43.
- Berlin I, Singleton EG, Heishman SJ. Predicting smoking relapse with a multidimensional versus a single-item tobacco craving measure. *Drug Alcohol Depend*. 2013;132(3):513–20.
- Westman EC, Behm FM, Simel DL, Rose JE. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. *Arch Intern Med*. 1997;157(3):335–40.
- Hymowitz N, Cummings KM, Hyland A, Lynn WR, Pechacek TF, Hartwell TD. Predictors of smoking cessation in a cohort of adult smokers followed for five years. *Tob Control*. 1997;6(Suppl 2):S57–62.
- Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, et al. Bupropion for smoking cessation: predictors of successful outcome. *Chest*. 2001;119(5):1357–64.
- Paluck EC, McCormack JP, Ensom MH, Levine M, Soon JA, Fielding DW. Outcomes of bupropion therapy for smoking cessation during routine clinical use. *Ann Pharmacother*. 2006;40(2):185–90.
- Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. *Drug Alcohol Depend*. 1994;34(3):211–6.
- Batra A, Collins SE, Torchalla I, Schroter M, Buchkremer G. Multidimensional smoker profiles and their prediction of smoking following a pharmacobehavioral intervention. *J Subst Abuse Treat*. 2008;35(1):41–52.
- Haug S, Schaub MP, Schmid H. Predictors of adolescent smoking cessation and smoking reduction. *Patient Educ Couns*. 2014;95(3):378–83.
- Jayakrishnan R, Uutela A, Mathew A, Auvinen A, Mathew PS, Sebastian P. Smoking cessation intervention in rural Kerala, India: findings of a randomised controlled trial. *Asia Pac J Cancer Prevent*. 2013;14(11):6797–802.
- Reid MS, Jiang H, Fallon B, Sonne S, Rinaldi P, Turrigiano E, et al. Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: exploring predictors of outcome as clues toward treatment improvement. *Am J Drug Alcohol Abuse*. 2011;37(5):472–8.
- Dorner TE, Trostl A, Womastek I, Groman E. Predictors of short-term success in smoking cessation in relation to attendance at a smoking cessation program. *Nicotine Tob Res*. 2011;13(11):1068–75.
- Borland R, Yong HH, O'Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. *Nicotine Tob Res*. 2010;12(Suppl):S45–50.
- Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee do H, et al. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. *J Korean Med Sci*. 2007;22(6):1065–70.
- Stolz D, Scherr A, Seiffert B, Kuster M, Meyer A, Fagerstrom KO, et al. Predictors of success for smoking cessation at the workplace: a longitudinal study. *Respiration*. 2014;87(1):18–25.
- Kaleta D, Korytkowski P, Makowiec-Dabrowska T, Usidame B, Bak-Romaniszyn L, Fronczak A. Predictors of long-term smoking cessation: results from the global adult tobacco survey in Poland (2009–2010). *BMC Public Health*. 2012;12:1020.
- Haug S, Meyer C, Ulbricht S, Schorr G, Ruge J, Rumpf HJ, et al. Predictors and moderators of outcome in different brief interventions for smoking cessation in general medical practice. *Patient Educ Couns*. 2010;78(1):57–64.
- Sheffer CE, Stitzer M, Payne TJ, Applegate BW, Bourne D, Wheeler JG. Treatment for tobacco dependence for rural, lower-income smokers: outcomes, predictors, and measurement considerations. *Am J Health Promot*. 2009;23(5):328–38.
- Klein EG, Forster JL, Erickson DJ. Longitudinal predictors of stopping smoking in young adulthood. *J Adolesc Health*. 2013;53(3):363–7.
- Bauld L, Ferguson J, McEwen A, Hiscock R. Evaluation of a drop-in rolling-group model of support to stop smoking. *Addiction*. 2012;107(9):1687–95.

21. Kim YJ. Predictors for successful smoking cessation in Korean adults. *Asia Nurs Res*. 2014;8(1):1–7.
22. Prado GF, Lombardi EM, Bussacos MA, Arrabal-Fernandes FL, Terra-Filho M, Santos Ude P. A real-life study of the effectiveness of different pharmacological approaches to the treatment of smoking cessation: re-discussing the predictors of success. *Clinics (Sao Paulo)*. 2011;66(1):65–71.
23. Myung SK, Park JG, Bae WK, Lee YJ, Kim Y, Seo HG. Effectiveness of proactive Quitline service and predictors of successful smoking cessation: findings from a preliminary study of Quitline service for smoking cessation in Korea. *J Korean Med Sci*. 2008;23(5):888–94.
24. Belleudi V, Bargagli AM, Davoli M, Di Pucchio A, Pacifici R, Pizzi E, et al. Characteristics and effectiveness of smoking cessation programs in Italy. Results of a multicentric longitudinal study [in Italian]. *Epidemiol Prev*. 2007;31(2–3):148–57.
25. Smit ES, Hoving C, Schelleman-Offermans K, West R, de Vries H. Predictors of successful and unsuccessful quit attempts among smokers motivated to quit. *Addict Behav*. 2014;39(9):1318–24.
26. Jardin BF, Carpenter MJ. Predictors of quit attempts and abstinence among smokers not currently interested in quitting. *Nicotine Tob Res*. 2012;14(10):1197–204.
27. Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatment. *Addict Behav*. 2011;36(1–2):144–7.
28. Asvat Y, Cao D, Africk JJ, Matthews A, King A. Feasibility and effectiveness of a community-based smoking cessation intervention in a racially diverse, urban smoker cohort. *Am J Public Health*. 2014;104(Suppl 4):S620–7.
29. Bock BC, Papandonatos GD, de Dios MA, Abrams DB, Azam MM, Fagan M, et al. Tobacco cessation among low-income smokers: motivational enhancement and nicotine patch treatment. *Nicotine Tob Res*. 2014;16(4):413–22.
30. Shiffman S, Balabanis MH, Gwaltney CJ, Paty JA, Gnys M, Kassel JD, et al. Prediction of lapse from associations between smoking and situational antecedents assessed by ecological momentary assessment. *Drug Alcohol Depend*. 2007;91(2–3):159–68.
31. Japuntich SJ, Smith SS, Jorenby DE, Piper ME, Fiore MC, Baker TB. Depression predicts smoking early but not late in a quit attempt. *Nicotine Tob Res*. 2007;9(6):677–86.
32. al' Absi M, Carr SB, Bongard S. Anger and psychobiological changes during smoking abstinence and in response to acute stress: prediction of smoking relapse. *Int J Psychophysiol*. 2007;66(2):109–15.
33. Boudrez H, Hoengenaert JP, Nackaerts K, Messig M, Metcalfe M. Predictors of quit success in Belgian participants of a varenicline observational smoking cessation study. *Acta Clin Belg*. 2013;68(1):37–42.
34. Yasin SM, Masilamani R, Ming MF, Koh D. Predictors of smoking cessation among staff in public Universities in Klang Valley, Malaysia. *Asia Pac J Cancer Prev*. 2011;12(3):811–6.
35. Abdallah AS, Lam TH, Chan SK, Leung GM, Chi I, Ho WW, et al. Effectiveness of a mobile smoking cessation service in reaching elderly smokers and predictors of quitting. *BMC Geriatr*. 2008;8:25.
36. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation. Who will quit with and without the nicotine patch. *JAMA*. 1994;271(8):589–94.
37. Hardie TL, Moss HB, Lynch KG. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. *Addict Behav*. 2006;31(11):2030–7.
38. Kendler KS, Prescott CA. A population-based twin study of lifetime major depression in men and women. *Arch Gen Psychiatry*. 1999;56(1):39–44.
39. Morley KI, Lynskey MT, Madden PA, Treloar SA, Heath AC, Martin NG. Exploring the inter-relationship of smoking age-at-onset, cigarette consumption and smoking persistence: genes or environment? *Psychol Med*. 2007;37(9):1357–67.
40. Vink JM, Beem AL, Posthuma D, Neale MC, Willemsen G, Kendler KS, et al. Linkage analysis of smoking initiation and quantity in Dutch sibling pairs. *Pharmacogenomics J*. 2004;4(4):274–82.
41. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. *Nicotine Tob Res*. 1999;1(Suppl 2):S51–7 (discussion S69–70).
42. Vink JM, Smit AB, de Geus EJ, Sullivan P, Willemsen G, Hottenga JJ, et al. Genome-wide association study of smoking initiation and current smoking. *Am J Hum Genet*. 2009;84(3):367–79.
43. Goode EL, Badzioch MD, Kim H, Gagnon F, Rozek LS, Edwards KL, et al. Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study. *BMC Genet*. 2003;4(Suppl 1):S102.
44. Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. *Am J Med Genet B Neuropsychiatr Genet*. 2003;118B(1):48–54.
45. Lerman CE, Schnoll RA, Munafò MR. Genetics and smoking cessation improving outcomes in smokers at risk. *Am J Prevent Med*. 2007;33(6 Suppl):S398–405.
46. Osler M, Holst C, Prescott E, Sorensen TI. Influence of genes and family environment on adult smoking behavior assessed in an adoption study. *Genet Epidemiol*. 2001;21(3):193–200.
47. Mayhew KP, Flay BR, Mott JA. Stages in the development of adolescent smoking. *Drug Alcohol Depend*. 2000;59(Suppl 1):S61–81.
48. Hamilton AS, Lessov-Schlaggar CN, Cockburn MG, Unger JB, Cozen W, Mack TM. Gender differences in determinants of smoking initiation and persistence in California twins. *Cancer Epidemiol Biomarkers Prev*. 2006;15(6):1189–97.
49. Xian H, Scherrer JF, Madden PA, Lyons MJ, Tsuang M, True WR, et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. *Nicotine Tob Res*. 2003;5(2):245–54.
50. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet*. 2010;42(5):441–7.
51. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature*. 2008;452(7187):638–42.
52. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNA3-CHRNA6 and CYP2A6 affect smoking behavior. *Nat Genet*. 2010;42(5):448–53.
53. Berrettini W, Yuan X, Tozzi F, Song K, Francks C, Chilcoat H, et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. *Mol Psychiatry*. 2008;13(4):368–73.
54. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. *Nat Genet*. 2010;42(5):436–40.
55. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. *Transl Psychiatry*. 2012;2:e119.
56. Vrieze SI, McGue M, Iacono WG. The interplay of genes and adolescent development in substance use disorders: leveraging findings from GWAS meta-analyses to test developmental

- hypotheses about nicotine consumption. *Hum Genet.* 2012;131(6):791–801.
57. Vrieze SI, McGue M, Miller MB, Hicks BM, Iacono WG. Three mutually informative ways to understand the genetic relationships among behavioral disinhibition, alcohol use, drug use, nicotine use/dependence, and their co-occurrence: twin biometry, GCTA, and genome-wide scoring. *Behav Genet.* 2013;43(2):97–107.
 58. Vinkhuyzen AA, Wray NR, Yang J, Goddard ME, Visscher PM. Estimation and partition of heritability in human populations using whole-genome analysis methods. *Ann Rev Genet.* 2013;47:75–95.
 59. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. *Nature.* 1998;391(6663):173–7.
 60. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. *Pharmacogenomics J.* 2007;7(2):81–98.
 61. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. *Hum Mol Genet.* 2008;17(18):2834–48.
 62. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, et al. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. *Neuropsychopharmacology.* 2012;37(3):641–50.
 63. Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, et al. Organic cation transporter variation and response to smoking cessation therapies. *Nicotine Tob Res.* 2014;16(12):1638–46.
 64. Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, et al. Gender-stratified gene and gene-treatment interactions in smoking cessation. *Pharmacogenomics J.* 2012;12(6):521–32.
 65. Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, et al. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. *Pharmacogenet Genomics.* 2012;22(7):551–4.
 66. Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, et al. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. *Drug Alcohol Depend.* 2014;138:109–17.
 67. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafò MR. Pharmacogenetics of smoking cessation in general practice: results from the patch II and patch in practice trials. *Nicotine Tob Res.* 2011;13(3):157–67.
 68. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstein LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. *Am J Medical Genet B Neuropsychiatr Genet.* 2008;147B(6):712–9.
 69. Ray R, Mitra N, Baldwin D, Guo M, Patterson F, Heitjan DF, et al. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. *Neuropsychopharmacology.* 2010;35(6):1374–82.
 70. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. *Arch Gen Psychiatry.* 2008;65(6):683–93.
 71. Drgon T, Johnson C, Walther D, Albino AP, Rose JE, Uhl GR. Genome-wide association for smoking cessation success: participants in a trial with adjunctive denicotinized cigarettes. *Mol Med.* 2009;15(7–8):268–74.
 72. Uhl GR, Drgon T, Johnson C, Walther D, David SP, Aveyard P, et al. Genome-wide association for smoking cessation success: participants in the Patch in Practice trial of nicotine replacement. *Pharmacogenomics.* 2010;11(3):357–67.
 73. McGeary JE, Knopik VS, Hayes JE, Palmer RH, Monti PM, Kalman D. Predictors of relapse in a bupropion trial for smoking cessation in recently-abstinent alcoholics: preliminary results using an aggregate genetic risk score. *Subst Abuse.* 2012;6:107–14.
 74. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, et al. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. *Addiction.* 2013;108(12):2202–11.
 75. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. *Mol Med.* 2010;16(7–8):247–53.
 76. Uhl GR, Walther D, Musci R, Fisher C, Anthony JC, Storr CL, et al. Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. *Mol Psychiatry.* 2014;19(1):50–4.
 77. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clin Pharmacol Ther.* 2009;85(6):635–43.
 78. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. *Clin Pharmacol Ther.* 2010;87(5):553–7.
 79. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). *Addiction.* 2014;109(1):128–37.
 80. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, et al. Pharmacogenetic investigation of smoking cessation treatment. *Pharmacogenetics.* 2002;12(8):627–34.
 81. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. *Biol Psychiatry.* 2007;62(6):635–41.
 82. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. *PLoS Genet.* 2010;6(8):e1001053.
 83. Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al. The CHRNA5-CHRNA3-CHRNA4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. *Cancer Res.* 2009;69(17):6848–56.
 84. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. *Hum Mol Genet.* 2007;16(1):36–49.
 85. Weiss RB, Baker TB, Cannon DS, von Niederhausern A, Dunn DM, Matsunami N, et al. A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. *PLoS Genet.* 2008;4(7):e1000125.
 86. Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A, et al. Why do young women smoke? I: direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. *Mol Psychiatry.* 2006;11(3):312–22 (223).
 87. Liang Y, Salas R, Marubio L, Bercovich D, De Biasi M, Beaudet AL, et al. Functional polymorphisms in the human beta4 subunit of nicotinic acetylcholine receptors. *Neurogenetics.* 2005;6(1):37–44.
 88. Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, et al. Human neuronal acetylcholine receptor A5-A3-

- B4 haplotypes are associated with multiple nicotine dependence phenotypes. *Nicotine Tob Res.* 2009;11(7):785–96.
89. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B Neuropsychiatr Genet.* 2011;156B(3):275–84.
 90. Munafò MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. *Nicotine Tob Res.* 2011;13(10):982–8.
 91. Chen LS, Baker TB, Piper ME, Breslau N, Cannon DS, Doheny KF, et al. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNA4) and cessation treatments in smoking cessation success. *Am J Psychiatry.* 2012;169(7):735–42.
 92. Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. *Pharmacogenet Genomics.* 2013;23(2):94–103.
 93. Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Ameli N, et al. Response to transdermal selegiline smoking cessation therapy and markers in the 15q24 chromosomal region. *Nicotine Tob Res.* 2015. [Epub ahead of print].
 94. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine Tob Res.* 2008;10(4):717–29.
 95. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine Tob Res.* 2007;9(9):947–54.
 96. Yudkin P, Munafò M, Hey K, Roberts S, Welch S, Johnstone E, et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. *BMJ.* 2004;328(7446):989–90.
 97. Aveyard P, Brown K, Saunders C, Alexander A, Johnstone E, Munafò MR, et al. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. *Thorax.* 2007;62(10):898–903.
 98. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry.* 2009;66(11):1253–62.
 99. Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. *Neuropsychopharmacology.* 2006;31(1):231–42.
 100. Swan GE, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioral counseling and varenicline treatment for smoking cessation. *Am J Prevent Med.* 2010;38(5):482–90.
 101. Hall SM, Humfleet GL, Gorecki JA, Munoz RF, Reus VI, Prochaska JJ. Older versus younger treatment-seeking smokers: differences in smoking behavior, drug and alcohol use, and psychosocial and physical functioning. *Nicotine Tob Res.* 2008;10(3):463–70.
 102. Killen JD, Fortmann SP, Murphy GM Jr, Hayward C, Fong D, Lowenthal K, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. *Addiction.* 2010;105(9):1660–8.
 103. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. *J Pharmacol Exp Ther.* 1997;282(3):1608–14.
 104. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. *Drug Metab Dispos.* 2000;28(10):1222–30.
 105. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoeconomic and clinical aspects. *Pharmacol Ther.* 2007;116(3):496–526.
 106. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. *Pharmacogenomics J.* 2013;13(1):1–11.
 107. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. *Mol Psychiatry.* 2006;11(4):400–9.
 108. Bloom J, Hinrichs AL, Wang JC, von Weyarn LB, Kharasch ED, Bierut LJ, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. *Pharmacogenet Genomics.* 2011;21(7):403–16.
 109. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res.* 2002;4(2):149–59.
 110. Benowitz NL, Jacob P 3rd. Metabolism of nicotine to cotinine studied by a dual stable isotope method. *Clin Pharmacol Ther.* 1994;56(5):483–93.
 111. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. *Pharmacol Rev.* 2005;57(1):79–115.
 112. Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. *Epidemiol Rev.* 1996;18(2):188–204.
 113. Davis RA, Curvall M. Determination of nicotine and its metabolites in biological fluids: in vivo studies. In: Jacob JWG, editor. *Analytical determination of nicotine and related compounds and their metabolites.* Amsterdam: Elsevier Science; 1999. p. 583–643.
 114. Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. *Eur J Clin Pharmacol.* 2010;66(3):239–51.
 115. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. *Clin Pharmacol Ther.* 2004;76(1):64–72.
 116. Binnington MJ, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, et al. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. *Pharmacogenet Genomics.* 2012;22(6):429–40.
 117. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. *Nicotine Tob Res.* 2003;5(5):621–4.
 118. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine. *Pharmacogenet Genomics.* 2009;19(5):388–98.
 119. Johnstone E, Benowitz N, Cargill A, Jacob R, Hinks L, Day I, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. *Clin Pharmacol Ther.* 2006;80(4):319–30.
 120. Chenoweth MJ, Novalen M, Hawk LW Jr, Schnoll RA, George TP, Cinciripini PM, et al. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. *Cancer Epidemiol Biomarkers Prev.* 2014;23(9):1773–82.
 121. Sofuoglu M, Herman AI, Nadim H, Jatlow P. Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine. *Neuropsychopharmacology.* 2012;37(6):1509–16.
 122. Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. *Pediatrics.* 2008;122(3):e643–7.

123. St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, Azizyeh A, et al. Reproducibility of the nicotine metabolite ratio in cigarette smokers. *Cancer Epidemiol Biomarkers Prev.* 2012;21(7):1105–14.
124. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. *Cancer Epidemiol Biomarkers Prev.* 2006;15(10):1812–9.
125. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, et al. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. *Clin Pharmacol Ther.* 2001;69(1):72–8.
126. Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, Montgomery GW, et al. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. *Hum Mol Genet.* 2012;21(13):3050–62.
127. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. *Clin Pharmacol Therap.* 2008;84(3):320–5.
128. Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med.* 2015;3(2):131–8.
129. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. *Clin Pharmacol Ther.* 2006;79(6):600–8.
130. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. *Pharmacol Biochem Behav.* 2009;92(1):6–11.
131. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, et al. Associations of CYP2A6 genotype with smoking behaviors in southern China. *Addiction.* 2011;106(5):985–94.
132. Kubota T, Nakajima-Taniguchi C, Fukuda T, Funamoto M, Maeda M, Tange E, et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. *Pharmacogenomics J.* 2006;6(2):115–9.
133. Tang DW, Hello B, Mroziwicz M, Fellows LK, Tyndale RF, Dagher A. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. *Neuroimage.* 2012;60(4):2136–43.
134. Bloom AJ, Martinez M, Chen LS, Bierut LJ, Murphy SE, Goate A. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. *PLoS One.* 2013;8(11):e79700.
135. Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, et al. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. *Clin Pharmacol Ther.* 2012;92(6):771–7.
136. Froeliger B, Kozink RV, Rose JE, Behm FM, Salley AN, McClernon FJ. Hippocampal and striatal gray matter volume are associated with a smoking cessation treatment outcome: results of an exploratory voxel-based morphometric analysis. *Psychopharmacology.* 2010;210(4):577–83.
137. McClernon FJ, Hiott FB, Liu J, Salley AN, Behm FM, Rose JE. Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: results of a preliminary functional magnetic resonance imaging study. *Addict Biol.* 2007;12(3–4):503–12.
138. Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. *Biol Psychiatry.* 2010;67(8):722–9.
139. Hartwell KJ, Lematty T, McRae-Clark AL, Gray KM, George MS, Brady KT. Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study. *Am J Drug Alcohol Abuse.* 2013;39(2):92–8.
140. Versace F, Engelmann JM, Robinson JD, Jackson EF, Green CE, Lam CY, et al. Prequit FMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome. *Nicotine Tob Res.* 2014;16(6):697–708.
141. Krishnan-Sarin S, Balodis IM, Kober H, Worhunsky PD, Liss T, Xu J, et al. An exploratory pilot study of the relationship between neural correlates of cognitive control and reduction in cigarette use among treatment-seeking adolescent smokers. *Psychol Addict Behav.* 2013;27(2):526–32.
142. Wheelock MD, Reid MA, To H, White DM, Cropsey KL, Lahti AC. Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings. *Front Pharmacol.* 2014;5:158.
143. Loughhead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R, et al. Working memory-related neural activity predicts future smoking relapse. *Neuropsychopharmacology.* 2015;40(6):1311–20.
144. Mashhoon Y, Janes AC, Jensen JE, Prescott AP, Pachas G, Renshaw PF, et al. Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. *Prog Neuropsychopharmacol Biol Psychiatry.* 2011;35(7):1709–13.
145. Brody AL, Mukhin AG, Shulenberg S, Mamoun MS, Kozman M, Phuong J, et al. Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. *Neuropsychopharmacology.* 2013;38(8):1548–56.
146. Brody AL, Mukhin AG, Mamoun MS, Luu T, Neary M, Liang L, et al. Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial. *JAMA Psychiatry.* 2014;71(7):797–805.
147. Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, et al. Biomarkers for smoking cessation. *Clin Pharmacol Ther.* 2013;93(6):526–38.